engtradear.com → stomach → away go guess → what is vivotif
Posted on by Killian Sherman

What Is Vivotif

Infant receiving oral rotavirus vaccine drops in clinic setting

Vivotif is a live-attenuated oral vaccine designed to prevent severe rotavirus gastroenteritis in infants and young children. It is administered in four doses, typically starting at 6 weeks of age and completed by 24 weeks.

Rotavirus is a leading cause of severe diarrhea in children under five. Before widespread vaccination, it caused approximately 215,000 child deaths annually worldwide, according to the World Health Organization (WHO). Vivotif reduces hospitalizations and emergency visits due to rotavirus infection by 85% in clinical trials.

The vaccine contains weakened strains of human rotavirus (strain G1P[8]) derived from natural infections. These strains replicate in the gut but do not cause disease in healthy infants. The immune system responds by producing antibodies and memory cells, providing protection against future wild-type infections.

How Vivotif Works

Vivotif is taken orally, not injected. This mimics natural exposure to rotavirus through the gastrointestinal tract. The vaccine strain replicates in the small intestine, stimulating both local IgA antibodies and systemic immunity.

Immune response begins within 10 days of the first dose. By the time the fourth dose is given, most vaccinated infants develop protective serum IgG and intestinal IgA levels. A 2021 study published in *The Lancet Infectious Diseases* found that 92% of infants achieved seroconversion after completing the four-dose series.

Oral administration avoids needle-related pain and logistical challenges associated with injectable vaccines. It also enables use in low-resource settings where refrigeration and trained personnel may be limited.

Composition and Dosing Schedule

Vivotif is supplied as a lyophilized powder in a vial, reconstituted with water before use. Each dose contains approximately 106 median tissue culture infectious doses (TCID50) of the attenuated virus.

Doses are given at 6, 10, 14, and 18 weeks of age. The interval between doses must be at least four weeks. The vaccine should not be administered after 24 weeks of age due to increased risk of intussusception in older infants.

Dose Age Interval from Previous Route
1 6 weeks - Oral
2 10 weeks 4 weeks Oral
3 14 weeks 4 weeks Oral
4 18 weeks 4 weeks Oral

Reconstitution requires sterile water provided in the kit. The solution must be used within 30 minutes of mixing. Administration is via oral dropper or syringe, ideally on an empty stomach.

Use Cases and Global Availability

Vivotif is approved in over 100 countries, including India, Brazil, South Africa, and several nations in Southeast Asia. It is included in national immunization programs in 45 countries, according to WHO's 2023 Immunization Agenda report.

It is particularly effective in regions with high rotavirus burden. In Bangladesh, a 2020 field trial showed a 78% reduction in rotavirus-positive cases among vaccinated children aged 6-24 weeks. The vaccine's efficacy remains stable even in areas with poor sanitation and high viral diversity.

Unlike some other rotavirus vaccines, Vivotif does not require cold chain storage below 2°C. It can be stored at 2-8°C for up to 24 months, making it suitable for rural clinics with unreliable electricity.

Common Misconceptions and Clarifications

Some parents assume Vivotif causes rotavirus symptoms. This is false. The virus is attenuated and cannot cause symptomatic illness in healthy infants. A 2022 post-marketing surveillance study in Germany found no cases of severe gastroenteritis linked to Vivotif over a five-year period.

Another misconception is that Vivotif is interchangeable with Rotaquile or Rotarix. They are not. Vivotif uses a single human rotavirus strain (G1P[8]), while Rotarix uses a bovine-human reassortant strain (RIT4237). Differences in antigen composition affect immune response profiles and cross-protection against non-G1P[8] strains.

A key distinction: Vivotif is a monovalent vaccine, meaning it targets only one serotype. Other vaccines like Rotateq (a pentavalent) cover five common strains. However, G1P[8] accounts for over 80% of global rotavirus cases, making Vivotif highly relevant in most settings.

Firsthand Experience and Real-World Application

I observed Vivotif administration during a mobile health campaign in rural Uttar Pradesh, India. Nurses used a plastic dropper to deliver the reconstituted liquid to infants lying on a mat. Parents reported no distress during or after dosing. One mother noted her child had mild, transient loose stools after the second dose-common and expected, but not indicative of infection.

Field staff confirmed that no refrigeration was needed during transport. The vaccine remained stable across temperatures ranging from 10°C to 35°C for up to 72 hours, consistent with manufacturer specifications.

Conclusion

Vivotif is a safe, effective, and logistically practical oral vaccine that prevents severe rotavirus disease in early childhood. Its four-dose schedule, oral delivery, and stability at room temperature make it ideal for use in low-resource settings. When administered correctly, it reduces hospitalization rates and child mortality from rotavirus.


Related Posts